Merit Medical Q2 revenue up 13.2% to $382.5M; non-GAAP EPS $1.01, up 9.8%; appoints new CEO

MERIT MEDICAL SYSTEMS INC

2025-Q2 EPS reported $1.03 revenue$737,813,000

Revenue $382.5M, +13.2% YoY; constant-currency revenue +12.5%, organic constant-currency +6.7%.
GAAP EPS $0.54 (-11.6%), non-GAAP EPS $1.01 (+9.8%); GAAP operating margin 12.3% vs 13.6% prior year.
Non-GAAP operating margin improved to 21.2% from 20.1%; free cash flow $89.1M in H1 2025, +8.1%.
Acquired Biolife (StatSeal/WoundSeal hemostatic devices); no transaction value disclosed.
Martha Aronson named President & CEO, effective Oct 3, 2025; Fred Lampropoulos becomes Chairman.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.